Results 31 to 40 of about 3,844,628 (256)

HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus

BMC Endocrine Disorders, 2022
Background The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM.  Methods A retrospective cohort study was conducted using
Marina Angel, Yelena Petrosyan, Mary-Anne Doyle, Curtis Cooper   +3 more
doaj   +1 more source

The use of sofosbuvir for the treatment of recurrent hepatitis C after liver transplantation

Трансплантология (Москва), 2017
The article presents the experience of direct-acting antiviral (DAA) drug treatment for hepatitis C in the patients after liver transplantation. The end-stage liver disease caused by hepatitis C is the main indication for orthotopic liver transplantation
M. Sh. Khubutiya, V. E. Syutkin, S. V. Zhuravel', M. S. Novruzbekov, A. B. Fedin, A. A. Salienko   +5 more
doaj   +1 more source

All-oral direct acting antiviral regimens available for clinical use.

, 2015
*24 weeks of treatment; DAA, direct-acting antiviral; GT1 (a/b), genotype-1; GT2, genotype-2; GT3, genotype-3All-oral direct acting antiviral regimens available for clinical use.
Susanna Naggie (304827), Stacy M. Horner (178713)   +1 more
core   +1 more source

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. [PDF]

, 2023
BACKGROUND Individuals with HIV and hepatitis C virus (HCV) who remain untreated with direct-acting antivirals can contribute to HCV transmission and HCV-related mortality.
Salmon, Dominique, Hellard, Margaret, van der Valk, Marc, Martinello, Marianne, Matthews, Gail V, Stewart, Ashleigh, Klein, Marina B, Rauch, Andri, Stoove, Mark, Schinkel, Janke, Wittkop, Linda, Berenguer, Juan, Sacks-Davis, Rachel, Smit, Colette, Boyd, Anders, Isfordink, Cas J, Lacombe, Karine, Doyle, Joseph S, van Santen, Daniela K, Daniela K van Santen, Marianne Martinello, Colette Smit, Karine Lacombe, Joseph S Doyle, Cas J Isfordink, Mark Stoove, Gail V Matthews, Dominique Salmon, Andri Rauch, Linda Wittkop, Marc van der Valk, Ashleigh Stewart, Anders Boyd, Juan Berenguer, Janke Schinkel, Marina B Klein, Margaret Hellard, Rachel Sacks-Davis   +37 more
core   +2 more sources

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment

Annals of Hepatology, 2018
Introduction. Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA ...
Stefano Gitto, Arrigo F.G. Cicero, Elisabetta Loggi, Marina Giovannini, Fabio Conti, Elena Grandini, Valeria Guarneri, Alessandra Scuteri, Giovanni Vitale, Carmela Cursaro, Claudio Borghi, Pietro Andreone   +11 more
doaj   +1 more source

Hepatitis C Direct-Acting Antiviral.

, 2016
FDA approved direct-acting antiviral treatment for hepatitis C. HCV RNA is translated into a long polyprotein which consists of three structural proteins and seven non-structural (NS) proteins.
Martha Pavlakis (3153936), Nahel Elias (3153927), Meghan E. Sise (731751), Anil Chandraker (3153945), Steve Gabardi (3153954), Eliot C. Heher (3153942), Anna E. Rutherford (3153930), Michael P. Curry (3153957), Leonardo V. Riella (613107), Raymond T. Chung (214536), Ming V. Lin (3153939), Jasmine M. Hanifi (3153951), Donald Chute (3153948), Beth M. Amundsen (3153933)   +13 more
core   +1 more source

Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study. [PDF]

Background The impact of treatment on hepatitis C virus with direct-acting antivirals on 90-day postoperative outcomes, overall survival, and recurrence-free survival in patients after liver resection for hepatocellular carcinoma is unknown.
Tabrizian, Parissa, Claasen, Marco, Sapisochin, Gonzalo, Singal, Amit G, Hansen, Bettina, Choi, Woo Jin, Tadros, Meena, Parikh, Neehar D, Pillai, Anjana, Hunold, Thomas M, Magyar, Christian T. J., Reig, Maria, Myers, Bryan, Ferrer Fàbrega, Joana, Rocha, Chiara, Feld, Jordan J, Li, Zhihao, Patel, Madhukar S, Ivanics, Tommy, Holgin, Victor, Vogel, Arndt, O'Kane, Grainne M   +21 more
core   +4 more sources

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Frontiers in Medicine, 2019
Hepatitis C virus (HCV) infection is a systemic disorder that frequently associates with extrahepatic manifestations, including nephropathies. Cryoglobulinemia is a typical extrahepatic manifestation of HCV infection that often involves kidneys with a ...
Andrea Angeletti, Chiara Cantarelli, Paolo Cravedi   +2 more
doaj   +1 more source

New drugs in the treatment of chronic hepatitis C [PDF]

Farmacia Hospitalaria, 2014
Objectives: To analyze the efficacy and safety of the new direct antiviralagents (DAA) that will become the new therapeutic arsenal for thetreatment of hepatitis C. Methods:We carried out a research in the electronic database with thefollowing criteria:
R. Jimenez Galan, Á. Albacete Ramirez, P. Monje Agudo, Y. Borrego Izquierdo, R. Morillo Verdugo   +4 more
doaj   +1 more source

Predictors of initiation of direct-acting antiviral treatment by Cox regression analysis.

, 2019
Predictors of initiation of direct-acting antiviral treatment by Cox regression analysis.
David Muschi (7300049), Paul Y. Kwo (7300040), Amy Puenpatom (4800831), Siu L. Hui (7300043), Zuoyi Zhang (6874895), Andrea A. Kelley (7300046)   +5 more
core   +1 more source